Le Lézard
Classified in: Health
Subject: SHM

CE Brands Inc. Announces Completion of 10:1 Share Consolidation


CALGARY, AB, Jan. 24, 2024 /CNW/ - CE Brands Inc. (TSXV: CEBI) ("CE Brands" or the "Company") announces the consolidation of its common shares on the basis of one (1) post-consolidation common share for every ten (10) pre-consolidation shares issued and outstanding as of the close of business on January 24, 2023. The shares are expected to begin trading on a consolidated basis on the TSX Venture Exchange on Friday, January 26, 2024. The share consolidation was approved by the Company's shareholders at the annual and special meeting held on December 4, 2024.

The Corporation shareholders will receive one (1) post-consolidation common share for every ten (10) pre-consolidation shares held by them. No fractional shares will be issued as a result of the consolidation. Fractional interests will be rounded to the nearest whole number of shares without any consideration payable therefor.

The new ISIN number for the post-consolidation shares is CA12513R3036. CE Brands' common shares will continue to trade under the symbol "CEBI" and CE Brands' name will not change.

A letter of transmittal will be sent to registered shareholders. Shareholders who hold their shares in brokerage accounts are not required to take any action to effect an exchange of their common shares.

About the Company

The Company develops products with leading manufacturers and iconic brand licensors by utilizing proprietary data that identifies key market opportunities.

Neither the TSX Venture Exchange nor its regulation services provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information, please visit the website at www.cebrands.co

Forward-looking Information

This press release may contain forward-looking information within the meaning of securities legislation, concerning the Company's business and affairs. In certain cases, forward-looking information can be identified by the use of words such as "plans", "expects" or "does not expect", "intends", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or variations of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur", or "be achieved".

Statement of past performance should not be construed as an indication of future performance. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. this press release includes forward-looking information with respect to CE Brands' plans to mail the transmittal letter and the expected date that the shares will begin trading on a consolidated basis. A number of factors, including those discussed above, could cause actual results to differ materially from the results discussed in the forward-looking statements. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on such forward-looking statements. Forward-looking information is provided as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as may be required under applicable securities legislation.

SOURCE CE Brands Inc.


These press releases may also interest you

at 03:05
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships...

at 03:05
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage...

at 02:50
Two hospitals in Belgium are successfully live with the public cloud service from international medical imaging IT and cybersecurity company Sectra (STOCKHOLM: SECT-B). As the first to use Sectra One Cloud in the Benelux countries, the two hospitals...

at 02:03
Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the...

at 02:00
July 3, 2024 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of...

at 01:39
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...



News published on and distributed by: